Chemotherapy to potentiate the radiation-induced immune response.
Fiche publication
Date publication
février 2023
Journal
International review of cell and molecular biology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ADOTEVI Olivier, Dr MIRJOLET Céline, Dr BOUSTANI Jihane
Tous les auteurs :
Lecoester B, Wespiser M, Marguier A, Mirjolet C, Boustani J, Adotévi O
Lien Pubmed
Résumé
Chemoradiation (CRT) is a conventional therapy used in local cancers, especially when they are locally advanced. Studies have shown that CRT induces strong anti-tumor responses involving several immune effects in pre-clinical models and humans. In this review, we have described the various immune effects involved in CRT efficacy. Indeed, effects such as immunological cell death, activation and maturation of antigen-presenting cells, and activation of an adaptive anti-tumor immune response are attributed to CRT. As often described in other therapies, various immunosuppressive mechanisms mediated, in particular, by Treg and myeloid populations may reduce the CRT efficacy. We have therefore discussed the relevance of combining CRT with other therapies to potentiate the CRT-induced anti-tumor effects.
Mots clés
Cancer, Chemoradiation, Chemotherapy, Combination, Radiotherapy
Référence
Int Rev Cell Mol Biol. 2023 02 11;376:143-173